Cargando…
Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience
Background: The sodium–glucose cotransporter-2 inhibitors (SGLT2i) have emerged as a crucial therapeutic option for patients with chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate, in a real-world population from a single centre, the feasibility of i...
Autores principales: | Tabella, Erika, Correale, Michele, Alcidi, Gianmarco, Pugliese, Rosanna, Ioannoni, Sara, Romano, Matteo, Palmieri, Gianpaolo, Di Biase, Matteo, Brunetti, Natale Daniele, Iacoviello, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514827/ https://www.ncbi.nlm.nih.gov/pubmed/37736926 http://dx.doi.org/10.3390/clinpract13050090 |
Ejemplares similares
-
Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction
por: Alcidi, Gianmarco, et al.
Publicado: (2023) -
Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure
por: Alcidi, Gianmarco, et al.
Publicado: (2022) -
Renal resistance index independently predicts worsening of renal function after coronary angiography
por: Barone, Roberta, et al.
Publicado: (2022) -
SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century?
por: Correale, Michele, et al.
Publicado: (2023) -
Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)